Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599).

Autor: Mercier J; UCB Pharma, Braine L'Alleud, Belgium., Bani M; UCB Pharma, Braine L'Alleud, Belgium., Colson AO; UCB Pharma, Braine L'Alleud, Belgium., Germani M; UCB Pharma, Braine L'Alleud, Belgium., Lalla M; UCB Pharma, Braine L'Alleud, Belgium.; OxSonics, Oxford, UK., Plisson C; Invicro, London, UK., Huiban M; Invicro, London, UK., Searle G; Invicro, London, UK., Mathy FX; UCB Pharma, Braine L'Alleud, Belgium., Nicholl R; UCB Pharma, Slough, UK., Otoul C; UCB Pharma, Braine L'Alleud, Belgium., Smit JW; UCB Pharma, Braine L'Alleud, Belgium.; Curare Consulting, Hamburg, Germany., van Asch V; Auximines Clinical Solutions, Zemst, Belgium., Wagneur M; UCB Pharma, Braine L'Alleud, Belgium., Maguire RP; UCB Pharma, Braine L'Alleud, Belgium. paul.maguire@ucb.com.

Publikováno v: Molecular imaging and biology [Mol Imaging Biol] 2024 Apr; Vol. 26 (2), pp. 310-321. Date of Electronic Publication: 2023 Dec 18.

Translocator protein PET imaging in temporal lobe epilepsy: A reliable test-retest study using asymmetry index.

Autor: Mahmud M; Department of Brain Sciences, Imperial College London, London, United Kingdom., Wade C; Department of Brain Sciences, Imperial College London, London, United Kingdom., Jawad S; Department of Brain Sciences, Imperial College London, London, United Kingdom., Hadi Z; Department of Brain Sciences, Imperial College London, London, United Kingdom., Otoul C; Clinical Imaging Translational, UCB Pharma SA, Brussels, Belgium., Kaminski RM; Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland., Muglia P; GRIN Therapeutics, Brussels, Belgium., Kadiu I; Clinical Imaging Translational, UCB Pharma SA, Brussels, Belgium., Rabiner E; Translational Applications, Invicro LLC, London, United Kingdom., Maguire P; Clinical Imaging Translational, UCB Pharma SA, Brussels, Belgium., Owen DR; Department of Brain Sciences, Imperial College London, London, United Kingdom., Johnson MR; Department of Brain Sciences, Imperial College London, London, United Kingdom.

Publikováno v: Frontiers in neuroimaging [Front Neuroimaging] 2023 Apr 28; Vol. 2, pp. 1142463. Date of Electronic Publication: 2023 Apr 28 (Print Publication: 2023).

Dose–response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy

Autor: Boon, P ^*, Chauvel, P, Pohlmann-Eden, B, Otoul, C, Wroe, S

Publikováno v: In Epilepsy Research 2002 48(1):77-89

Evaluation of Sleep Disorders in Patients with Epilepsy: A Case-control Study.

Autor: Bostan, Seda¹, Algın, Demet İlhan² ilhandemet@gmail.com

Publikováno v: Archives of Epilepsy. 2024, Vol. 30 Issue 4, p120-126. 7p.

Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach.

Autor: Muglia P; UCB Pharma, Braine l'Alleud, Belgium., Hannestad J; UCB Pharma, Braine l'Alleud, Belgium., Brandt C; Department of General Epileptology, Bethel Epilepsy Centre, Mara Hospital, Bielefeld, Germany., DeBruyn S; UCB Pharma, Braine l'Alleud, Belgium., Germani M; UCB Pharma, Braine l'Alleud, Belgium., Lacroix B; UCB Pharma, Braine l'Alleud, Belgium., Majoie M; Department of Neurology, Academic Center of Epileptology Kempenhaeghe, Maastricht University Medical Centre, Maastricht, The Netherlands., Otoul C; UCB Pharma, Braine l'Alleud, Belgium., Sciberras D; UCB Pharma, Braine l'Alleud, Belgium., Steinhoff BJ; Kork Epilepsy Center, Kehl-Kork, Germany., Van Laere K; Department of Imaging and Pathology, KU, Leuven, Belgium., Van Paesschen W; Department of Neurology, University Hospital, Leuven, Belgium., Webster E; UCB Pharma, Raleigh, NC, USA., Kaminski RM; UCB Pharma, Braine l'Alleud, Belgium., Werhahn KJ; UCB Pharma, Monheim am Rhein, Germany., Toledo M; Epilepsy Unit, Department of Neurology, Vall d'Hebron Hospital, Barcelona, Spain.

Publikováno v: Brain communications [Brain Commun] 2020 Nov 02; Vol. 2 (2), pp. fcaa183. Date of Electronic Publication: 2020 Nov 02 (Print Publication: 2020).